1370261-98-5

Upstream product

• 1370261-95-2 tert-butyl (1S,2R)-2-(4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-5-carbamoylpyrimidin-2-ylamino)cyclohexylcarbamate 
• 64-19-7 acetic acid 
• 931-15-7 (1S,2S)-trans-2-aminocyclohexanol 
• 1194973-45-9 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(methylthio)pyrimidine-5-carboxamide 
• 365996-30-1 tert-butyl ((1S,2R)-2-aminocyclohexyl)carbamate 
• 40571-86-6 (+/-)-trans-2-(benzylamino)cyclohexanol 
• 1370261-93-0 ethyl 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(methylthio)pyrimidine-5-carboxylate 
• 364385-54-6 (1S,2R)-2-tert-Butoxycarbonylamino-cyclohexylamine 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 402-67-5 3-fluoro-1-nitrobenzene 
• 342623-98-7 2-(3-nitrophenyl)-2H-1,2,3-triazole 
• 626248-56-4 3-(2H-1,2,3-triazol-2-yl)aniline 
• 626-01-7 3-Iodoaniline 
• 365996-29-8 (1R,2S)-2-(N-tert-butyloxycarbonylamino)-1-azidocyclohexane 

Relevant academic research and scientific papers

CYCLOHEXANEDIAMINE COMPOUNDS AND METHODS FOR THEIR PREPARATION

The present invention provides processes for the preparation of cyclohexanediamine compounds of formula Ia and intermediates thereof. The compounds are useful as Syk kinase inhibitors and in various pharmaceutical compositions, and particularly useful for treating conditions mediated at least in part by Syk kinase activity.